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Purpose
To assess the usefulness of adenosine triphosphate-based chemotherapy response assay
(ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy. 
Materials and Methods
Sixty-two patients underwent curative surgical resection between January, 2006 and December,
2008. Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49
had successful assay results and they received either oral 5-fluorouracil or other chemo-
therapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-
fluorouracil and whose assays were successful.
Results
The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median
treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years
(range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according
to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-
group showed a significantly longer time to relapse (not reached in the sensitive-group vs.
24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the
resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group,
p=0.16, statistically insignificant).
Conclusion
Patients who receive curative surgical resection significantly benefit from sensitive adjuvant
chemotherapy according to ATP-CRA results for time to relapse.
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Introduction
Gastric cancer is the second most common cause of cancer-related
death in the world, the fifth most prevalent cancer worldwide [1],
and the leading cause of cancer-related death in eastern Asian
countries. Curative resection has been considered the most important
prognostic factor in advanced gastric cancer (AGC) [2], but most
patients are at risk of recurrence. Adjuvant therapies adopting single
or combined chemotherapy approaches with curative intent have
been widely examined, and several meta-analyses have
demonstrated modest survival benefits for adjuvant chemotherapy
[3,4]. Considering the toxicity of chemotherapies, properly choosing
drugs for patients who have undergone curative resection is
important. By far, postoperative chemotherapy in AGC after
curative resection has controversial survival benefits [5,6]. Thesefacts have led to the concept of individualized tumor response tests
(ITRT) [7] to increase the efficacy and feasibility of certain drugs
and to predict the prognosis and survival benefits of sensitive drugs. 
By definition, ITRT are any laboratory methods performed to
evaluate malignant cell growth inhibition by conventional chemo-
therapeutic agents [8]. Several methodologies for ITRT have been
developed including the adenosine triphosphate-based chemotherapy
response assay (ATP-CRA) and the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) chemosensitivity test (MTT
assay). These seem to be ideal tests that could help oncologists easily
select effective chemotherapeutic agents for patients with advanced
stage cancer. Surgeons in Japan have made use of the MTT assay
and obtained positive results for AGC patients undergoing both
adjuvant [9] and palliative chemotherapy [10]. In our study, we
adopted an ATP-CRA to predict the response of chemotherapeutic
agents. ATP-CRA is a sensitive assay that evaluates tumor cell
viability by measuring the intracellular ATP levels of drug-exposed
cells and untreated controls. This assay has been adopted for non-
small cell lung cancer [11], ovarian cancer [12], and breast cancer [13]
providing positive results in patients who underwent curative resection. 
Several types of oral 5-fluorouracil (FU) have been developed for
gastrointestinal (GI) tract cancer as a substitute for intravenous 5-FU
with comparable efficacies but lower toxicities: S-1, UFT, capeci-
tabine, and doxifluridine. S-1 and Tegracil are combinations of tegafur
(a prodrug that is converted by cells to fluorouracil), inhibitors of
dihydropyrimidine dehydrogenase (cholorodihydroxy pyridine in S-1
and uracil in Tegracil), and oxonic acid in S-1 [14]. Capecitabine
(Xeloda) is a prodrug of doxifluridine, which is converted to the active
FU by thymidine phosphorylase in tumor cells. The rate of response
to treatment with each of the oral 5-FUs ranges around 30% [15]. 
In this study, we retrospectively analyzed 24 patients who
underwent curative resection and postoperatively were treated with
oral 5-FU. To assess the feasibility of using the ATP-CRA assay in
adjuvant chemotherapy, we compared the relapse rate and survival
between sensitive and insensitive groups.
Materials and Methods
1 Patients
Sixty-two patients, who were diagnosed as having AGC under-
went curative surgery in Dong-A University Hospital between
January, 2006 and November, 2008. ATP-CRA was done on tumor
tissue specimens obtained from patients with pathologically
confirmed AGC. The eligible patients for this study were subjects
from whom we had successfully obtained assay results, who received
extended surgery for AGC, and who received more than one month
of 5-FU per os. The other eligibility criteria were: 1) aged at least 18
years; 2) histologically or cytologically proven AGC; 3) stage IB, II
or III [16]; 4) an Eastern Cooperative Oncology Group performance
status (ECOG PS) of 2; 5) adequate bone marrow function (neutro-
phils1.510
3/Ǻ L, platelets10010
3/Ǻ L, and Hb10.0 g/dL),
adequate renal function (serum creatinine1.5upper normal
limit), and adequate liver function (serum bilirubin1.5upper
normal limit, aspartate aminotransferase, and alanine amino-
transferase1.5upper normal limit); and 6) no history of other
malignancies during the observation time. This clinical trial was
approved by the appropriate Institutional Review Board, and all
patients in the study gave written informed consent.
2   ATP-based chemotherapy response assay methodology
1) Isolation of cancer cells, elimination of normal cells, and
tissue culture 
Tumor tissues stored in Hank balanced salt solution (Gibco,
Rockville, MD), containing 100 IU/mL penicillin (Sigma, St. Louis,
MO), 100 Ǻ g/mL streptomycin (Sigma), 100 Ǻ g/mL gentamicin
(Gibco), 2.5 Ǻ g/mL amphotericin B (Gibco), and 5% fetal bovine
serum (FBS, Gibco) were delivered to the laboratory. These tissues
were washed, quantified, and minced, and then incubated with
extracellular matrix degrading enzymes, such as dispase (Sigma),
pronase (Sigma), and DNase (Sigma), at 37.8 for 12 to 16 hours.
Cells were harvested using a cell strainer (BD Falcon, Bedford, MA).
To eliminate red blood cells and dead cells, the cell suspensions
were subjected to Ficoll (1.077 g/mL) gradient centrifugation at 400 g
for 15 minutes. The viability of isolated cells was tested using
Trypan blue exclusion. The histological types of the tumor tissues as
well as qualitative and quantitative analyses of the cancer cells were
evaluated by pathologists.
2) ATP measurement
Separated tumor cells were diluted to 2,000-20,000 viable cells/
100 Ǻ L using Iscove modified Dulbecco medium (IMDM, Gibco),
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CST fail
(n=13)
CST success
(n=49)
Non-oral 5-FU
(n=25)
Oral 5-FU
(n=24)
Curative operation
(excluding stage IV)
(n=62)
Fig. 1. Patient selection. Non-oral 5-fluorouracil (5-FU) contains
patients who did not receive chemotherapy and who were treated
with other chemotherapies. CST, chemosensitivity test.Ji Hyun Lee, et al_ATP-CRA in AGC with Oral 5-FU
VOLUME 43  NUMBER 2  JUNE  2011   119
U
P
N
S
e
x
A
g
e
 
(
y
r
)
O
p
 
d
a
t
e
O
p
H
i
s
t
o
l
o
g
y
S
t
a
g
e
T
N
C
T
x
 
s
t
a
r
t
 
d
a
t
e
R
e
l
a
p
s
e
T
T
P
 
(
m
o
)
C
e
n
s
o
r
S
e
n
s
i
t
i
v
i
t
y
1
M
5
3
2
0
0
6
-
3
-
2
3
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
w
e
l
l
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
6
-
0
4
-
2
0
N
o
A
l
i
v
e
Y
e
s
2
F
7
2
2
0
0
6
-
4
-
1
0
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
6
-
0
4
-
2
0
N
o
A
l
i
v
e
Y
e
s
3
M
6
7
2
0
0
6
-
9
-
2
5
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
w
e
l
l
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
2
1
2
0
0
6
-
1
0
-
1
0
N
o
A
l
i
v
e
Y
e
s
4
M
5
6
2
0
0
6
-
1
1
-
1
7
L
A
D
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
6
-
1
2
-
1
9
N
o
A
l
i
v
e
Y
e
s
5
F
6
0
2
0
0
6
-
1
1
-
2
9
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
6
-
1
2
-
2
8
Y
e
s
1
7
.
5
7
D
e
a
d
Y
e
s
6
M
5
4
2
0
0
6
-
1
1
-
3
0
R
S
G
M
u
c
i
n
u
s
 
a
d
e
n
o
c
a
r
c
i
n
o
m
a
3
A
3
1
2
0
0
7
-
0
1
-
0
4
N
o
A
l
i
v
e
Y
e
s
7
M
6
4
2
0
0
6
-
1
2
-
2
8
L
A
D
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
w
e
l
l
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
7
-
0
1
-
2
5
N
o
A
l
i
v
e
N
o
8
F
4
6
2
0
0
7
-
3
-
2
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
3
A
2
2
2
0
0
7
-
0
3
-
3
0
Y
e
s
4
.
4
3
D
e
a
d
N
o
9
M
6
9
2
0
0
7
-
4
-
1
6
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
w
e
l
l
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
2
1
2
0
0
7
-
0
5
-
1
7
N
o
A
l
i
v
e
Y
e
s
1
0
M
5
2
2
0
0
7
-
5
-
1
8
L
A
D
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
7
-
0
6
-
1
4
N
o
A
l
i
v
e
Y
e
s
1
1
F
3
0
2
0
0
7
-
5
-
2
8
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
3
0
2
0
0
6
-
0
6
-
2
6
Y
e
s
2
4
.
8
0
D
e
a
d
N
o
1
2
M
7
0
2
0
0
7
-
6
-
2
2
L
A
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
7
-
0
7
-
1
9
N
o
A
l
i
v
e
N
o
1
3
M
7
0
2
0
0
7
-
9
-
3
L
A
D
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
2
1
2
0
0
7
-
1
0
-
0
2
N
o
A
l
i
v
e
Y
e
s
1
4
M
5
2
2
0
0
8
-
1
-
1
6
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
3
A
2
2
2
0
0
8
-
0
2
-
1
9
N
o
A
l
i
v
e
Y
e
s
1
5
F
7
7
2
0
0
8
-
4
-
1
4
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
3
0
2
0
0
8
-
0
5
-
2
2
N
o
A
l
i
v
e
Y
e
s
1
6
M
7
7
2
0
0
8
-
5
-
2
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
w
e
l
l
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
3
A
3
1
2
0
0
8
-
0
5
-
2
9
Y
e
s
8
.
4
3
A
l
i
v
e
N
o
1
7
M
7
7
2
0
0
8
-
5
-
9
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
w
e
l
l
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
2
1
2
0
0
8
-
0
6
-
0
5
N
o
A
l
i
v
e
Y
e
s
1
8
F
6
5
2
0
0
8
-
5
-
1
9
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
3
B
3
2
2
0
0
8
-
0
6
-
1
7
N
o
A
l
i
v
e
Y
e
s
1
9
F
4
2
2
0
0
8
-
5
-
2
3
L
A
D
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
1
B
2
0
2
0
0
8
-
0
6
-
1
9
N
o
A
l
i
v
e
N
o
2
0
M
7
3
2
0
0
8
-
5
-
2
3
R
S
G
P
a
p
i
l
l
a
r
y
 
a
d
e
n
o
c
a
r
c
i
n
o
m
a
1
B
2
0
2
0
0
8
-
0
6
-
1
8
N
o
A
l
i
v
e
N
o
2
1
M
7
8
2
0
0
8
-
6
-
9
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
2
1
2
0
0
8
-
0
7
-
0
8
N
o
A
l
i
v
e
Y
e
s
2
2
M
7
3
2
0
0
8
-
8
-
2
2
R
T
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
2
1
2
0
0
8
-
0
9
-
2
4
N
o
A
l
i
v
e
Y
e
s
2
3
F
6
4
2
0
0
8
-
9
-
1
0
R
S
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
m
o
d
e
r
a
t
e
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
3
A
2
2
2
0
0
8
-
1
0
-
0
6
N
o
A
l
i
v
e
N
o
2
4
M
8
1
2
0
0
8
-
1
0
-
7
L
A
D
G
A
d
e
n
o
c
a
r
c
i
n
o
m
a
,
 
p
o
o
r
l
y
 
d
i
f
f
e
r
e
n
t
i
a
t
e
d
2
3
0
2
0
0
8
-
1
1
-
0
1
N
o
A
l
i
v
e
Y
e
s
U
P
N
,
 
u
n
i
q
u
e
 
p
a
t
i
e
n
t
 
n
u
m
b
e
r
;
 
O
p
,
 
o
p
e
r
a
t
i
o
n
;
 
C
T
x
,
 
c
h
e
m
o
t
h
e
r
a
p
y
;
 
T
T
P
,
 
t
i
m
e
 
t
o
 
p
r
o
g
r
e
s
s
i
o
n
;
 
S
e
n
s
i
t
i
v
i
t
y
,
 
c
h
e
m
o
s
e
n
s
i
t
i
v
i
t
y
 
t
o
 
5
-
f
l
u
o
r
o
u
r
a
c
i
l
;
 
M
,
 
m
a
l
e
;
 
F
,
 
f
e
m
a
l
e
;
 
R
S
G
,
 
r
a
d
i
c
a
l
 
s
u
b
t
o
t
a
l
 
g
a
s
t
r
e
c
t
o
m
y
;
 
L
A
D
G
,
 
l
a
p
a
r
o
s
c
o
p
e
-
a
s
s
i
s
t
e
d
 
d
i
s
t
a
l
g
a
s
t
r
e
c
t
o
m
y
;
 
R
T
G
,
 
r
a
d
i
c
a
l
 
t
o
t
a
l
 
g
a
s
t
r
e
c
t
o
m
y
.
 
T
a
b
l
e
 
1
.
 
B
a
s
i
c
 
p
a
t
i
e
n
t
 
d
a
t
aCancer Res Treat. 2011;43(2):117-123
120 CANCER  RESEARCH AND  TREATMENT
including 10% FBS, and seeded in triplicate into wells of a 96-well
ultra-low attachment plate (Costar, Cambridge, MA), which
restricted the growth of normal cells (e.g., fibroblasts). For the treated
groups, 100 Ǻ L of chemotherapeutic agents were added to the seeded
cell cultures and incubated for 48 hours in a CO2 incubator. For the
untreated control groups, 100 Ǻ L of IMDM, without chemotherapeutic
agents, were added. For quality control, a negative control group of
three to six wells (containing only seeding medium but without
cells), and two positive control groups were included in the culture
plate. Each positive control group was composed of three wells that
contained the minimal (105 pg ATP) and median (280 pg ATP)
amounts of ATP, as measured in 1,000 tumor cells harvested from
tissue. Treated drug concentrations (TDC, concentrations of treatment
drugs) were determined by preliminary experiments. They exhibited
a scattered distribution of cell death from each specimen. Drugs
were used in triplicate at 0.2, 1, and 5 TDC. The TDCs used
were: 5-FU (10 Ǻ g/mL), oxaliplatin (2.9 Ǻ g/mL), irinotecan (4.7 Ǻ g/mL),
cisplatin (2.5 Ǻ g/mL), carboplatin (12 Ǻ g/mL), paclitaxel (8.5 Ǻ g/mL),
docetaxel (3.7 Ǻ g/mL), gemcitabine (16.9 Ǻ g/mL), and vinorelbine
(0.18 Ǻ g/mL), which are all active drugs widely used in combination
with 5-FU in AGC. Eighteen cells from the untreated control and
from the treated groups were lysed, and the amount of ATP in the
cell lysates was measured using flash luminescence measurements
on a Victor 3 multilabel counter (PerkinElmer, Boston, MA). The
cell death rate for each drug was calculated using the following formula:
Cell death rate (%)=
[1- 
Mean luminescence in treated group             ]100
Mean luminescence in untreated control group  
A chemosensitivity index (CI) was calculated using the sum of
the percentages of cell deaths for all concentrations tested: CI=(300-
sum of % cell death rate at 0.2, 1 and 5 TDC).
Luminescence measurements were directly related to ATP levels;
they allowed for evaluation of the percentage of cell deaths with
respect to the untreated control. We did not use background sub-
traction because the quantity of ATP in the “media only” well
(dispensed medium without cells) and the quantity of extracellular
ATP were always negligible. The intra-assay mean coefficient of
variation (CV) was calculated using the luminescence value measured
three times in each specimen. If microorganism contamination was
present, if the intra-assay mean CV exceeded 30, or if the measure-
ment luminescence in the untreated control group was lower than
that in the positive control group (105 pg of ATP), the test was
considered a failure.
3 Chemotherapy
Patients were administered oral 5-FU four weeks after an
operation for AGC with curative intent. Oral 5-FUs that were ad-
ministered were Tegracil (Shinpoong Pharmaceutical, Ansan,
Korea) 300 mg/m
2/day in 15 patients, TS-1 (Jeil Pharmaceutical,
Seoul, Korea) 30 mg/m
2 bid. in two patients, Capecitabine (Roche
Pharmaceutical, Nutley, NJ) 1,250 mg/m
2 bid. in three patients, and
Doxifluridine bid in four patients. The mean duration of chemotherapy
administration was 10.76 months: 11.5 months in the S-group and
9.3 months in the R-group (p=0.978).
4 Endpoints and statistical analysis
The endpoints of our study were the correlations between (1) the
ATP-CRA results and (2) time to relapse (TTR) or overall survival
(OS). TTR was defined as the time from commencement of chemo-
therapy until disease progression or patient death. OS was defined as
the time from chemotherapy to death from all causes. 
All statistical calculations were carried out using the SPSS ver.
11.5 (SPSS Inc., Chicago, IL). All p-values were two-sided, and the
p-value for statistical significance was set at 0.05. Means and medians
were calculated when appropriate, continuous variables were
compared by Student’s t-test, and categorical variables were analyzed
by Ȅ
2 test. Survival was calculated using the Kaplan-Meier method.
A log-rank test was used to compare survival between subgroups.
Prognostic variables found by univariate analysis were used in
multivariate analysis by the Cox proportional hazard regression
model.
Table 2. Patient characteristics following ATP-CRA results for 5-FU
5-FU-sensitive 5-FU-resistant
(n=16) (n=8) p-value
No. % No. %
Median age (range, yr) 68 (52-81) 64 (30-77)
Gender             0.221
Male 12 75.0 4 50.0
Female 4 25.0 4 50.0
Stage 0.204
IB 5 31.2 4 50.0
II 8 50.0 1 12.5
III 3 18.8 3 37.5
Depth of tumor invasion 0.698
T2 12 75.0 6 75.0
T3 4 25.0 2 25.0
Lymph node metastasis 0.296
N0 7 43.8 5 62.5
N1 7 43.8 1 12.5
N2 2 12.4 2 25.0
Histological type adenocarcinoma 0.905
Well differentiated 4 25.0 2 25.0
Moderately differentiated 5 31.2 3 37.5
Poorly differentiated 6 37.5 2 25.0
Other 1 6.3 1 12.5
ATP-CRA, adenosine triphosphate-based chemotherapy response assay; FU,
fluorouracil.Ji Hyun Lee, et al_ATP-CRA in AGC with Oral 5-FU
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Results
1 Patient characteristics
From January, 2006 to December, 2008, 62 patients underwent
curative surgical resection for AGC. The success rate of the ATP-
CRA assay was 49 out of 62 (79%). Among the 49 successful ATP-
CRA patients, 21 received other chemotherapies and four patients
did not receive chemotherapy. A total of 24 patients was retrospec-
tively analyzed (Fig. 1). The median age was 66 years (range, 30 to
81 years) and the male to female ratio was 2 : 1. Patients were
grouped into sensitive- (S-) and resistant- (R-) groups according to
ATP-CRA results for 5-FU. There were no significant differences in
pretreatment factors between the subgroups. The clinicopathologic
data of patients are shown in Tables 1 and 2. 
2 TTR and OS according to ATP-CRA results
The median observation time was 22.6 months (range, 10.1 to
40.9 months). Four of 24 patients underwent disease progression. Of
these four, three patients expired due to cancer progression. The
median TTR did not reach the end point, with a two year TTR of
75%. The median OS was 23.3 months (95% confidence interval,
10.29 to 36.31) with a two year OS rate of 91%.  
Following the ATP-CRA results, the S-group showed significantly
longer TTR (not reached in the S-group vs. 24.8 months in the R-
group, p=0.043) and an insignificantly longer OS compared to the
R-group, (not reached in the S-group vs. 35.7 months in the R-
group, p=0.16) (Figs. 2 and 3).
3 Predictors for clinical response and prognostication
for progression or survival
Chemosensitivity result according to the ATP-CRA assay was the
only significant predictor for TTR, whereas there were no significant
pretreatment predictors in univariate analysis. In multivariate
analysis; however, there were no significant factors for prediction of
TTR and OS (data not shown). 
Discussion 
Since the development of the oral prodrug form of FU in 1967,
numerous studies have been conducted to demonstrate the efficacy
of the oral form of FU compared with protracted intravenous infusion
of FU. The discovery of dihydropyrimidine dehydrogenase (DPD)
in the catabolic pathway of FU led to the use of combinations of
inhibitors of DPD with the oral prodrug of FU, yielding a prolonged
activity of FU [15]. The invention of another form of oral prodrug of
FU, capecitabine, boosted the investigation of the oral form of FU in
GI tract tumors and other solid tumors of epithelial cell origin. A
recent study comparing continuous infusion of 5-FU and capeci-
tabine, the REAL-2 and ML17032 trials, showed that oral
fluoropyrimidine is non-inferior to 5-FU for OS and progression
free survival, respectively, in advanced oesophago-gastric cancer [17].
However, combinations of these various types of oral FU prodrugs
as a single agent have not undergone large scale randomized studies.
But, some pilot studies have shown that the response rate to each of
the prodrugs of GI tract tumors was approximately 30% [18,19]. In
this study, patients who underwent curative resection for AGC were
treated with various prodrug forms of oral fluoropyrimidine without
combination with other infusional chemotherapeutic agents as
adjuvant therapy. 
Previous intravenous combination chemotherapy for adjuvant
purposes in AGC revealed a negative result for disease free survival
or OS, but showed a high response rate [5]. However, studies in
Japan, ones making use of another in vitro assay (the MTT-assay),
produced a positive result in both response rate and in OS [9,10]. In
our study, although the number of patients who had undergone
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Fig. 2. Time to relapse according to chemosensitivity.
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Fig. 3. Overall survival rate according to chemosensitivity.ATP-CRA assays and had successful results was small, the clinical
outcomes of the chemosensitive group were more favorable than
those for TTR. The TTR and OS were not significantly different as
a function of cancer stage. The patients in the S- and R-groups had
similar pretreatment parameters in age, stage, depth of invasion,
nodal metastasis, and histological types, and there were no significant
differences in these factors. Previous studies have shown that an
anchorage-independent culture method, such as an agar underlayer,
inhibits the growth of fibroblasts, allowing tumor cells to survive
and proliferate. In our study, we adopted the use of another ultra-low
attachment plate, one that inhibits fibroblasts better than the agar
plate, which may have allowed a positive result. The beneficial
aspect of oral prodrug forms of FU in TTR may have additional
significance for the role of oral forms of FU in adjuvant chemo-
therapy of AGC, which is the primary concern of most oncologists.
Although ITRT-guided chemotherapy seems to be ideal, in
general clinical practice these methods are not widely accepted
because they require high technical skill, a large number of tumor
cells, and a long turnaround time for testing. ATP-CRA has a
relatively short turnaround time (a few days) and high success rates
even with bronchoscopic biopsy specimens in lung cancers [11]. We
have shortened the turnaround time to 48 hours and raised the drug
concentrations, which has been tried in other studies [20]. Hence,
clinicians can simply adopt the ATP-CRA in clinical trials. 
The validity of a diagnostic test to be applied in the clinical setting
is assessed by positive predictive value (PPV) and negative pre-
dictive value (NPV). For the ITRT used in our study, the ATP-CRA
assay showed a PPV of 94% and an NPV of 38%. This result is
opposite that of previous studies which have reported higher NPV
than PPV values [9,10]. Higher PPV than NPV values means that
the ATP-CRA assay can detect drug sensitivity better than drug
resistance. Although the heterogeneity of drug sensitivity in a tumor
specimen in patients may vary, complete removal of the tumor may
provide a comprehensive chemosensitivity of the malignant tissue.
The low NPV of the ATP-CRA assay may make clinicians avoid
the resistant drugs by the sensitivity test. The small number of
patients analyzed may have resulted in NPV that is less reliable, so
studies on chemosensitivity tests with a large number of patients are
needed to demonstrate the validity of the ATP-CRA. 
Conclusion
A limitation of our study was that the type of oral 5-FUs and the
duration of administration were not the same, creating different
pharmacokinetics and different drug levels in different individuals.
In this study, we compared very small numbers of patients that were
chemo-sensitive or resistant, and this assay cannot be easily generalized
to predict the outcome of chemotherapy. However, the positive
correlation of ATP-CRA results and clinical outcomes should en-
courage randomized, prospective studies with more patients that
compare ATP-CRA results and conventional adjuvant chemotherapies
in AGC patients that have undergone curative surgical treatments. 
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